Related Experiment Videos
Protein SAP (serum amyloid P-component) in Waldenström's macroglobulinaemia, multiple myeloma and rheumatic diseases
Abstract:
Serum amyloid P-component (protein SAP) levels in patients with Waldenström's macroglobulinaemia have been determined to be markedly elevated (83 +/- 34 micrograms/ml) compared with healthy adult controls (35 +/- 11 micrograms/ml) and patients with multiple myeloma (39 +/- 17 micrograms/ml). Seropositive rheumatoid arthritis and ankylosing spondylitis patients demonstrated slightly elevated protein SAP levels compared with normals and systemic lupus erythematosus patients, but these values were indistinguishable from those for patients with amyloidosis associated with a rheumatic disease.
Insights
Serum amyloid P-component (protein SAP) is significantly elevated in Waldenström's macroglobulinaemia patients. Protein SAP levels were also slightly higher in some rheumatic diseases compared to healthy individuals.
Area of Science:
- Biochemistry
- Immunology
- Hematology
Background:
- Serum amyloid P-component (protein SAP) is a constituent of all amyloid deposits.
- Elevated protein SAP levels have been observed in various inflammatory and malignant conditions.
Purpose of the Study:
- To quantify serum amyloid P-component (protein SAP) levels in patients with Waldenström's macroglobulinaemia.
- To compare protein SAP levels in Waldenström's macroglobulinaemia with those in multiple myeloma, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, and healthy controls.
Main Methods:
- Serum samples were collected from patients and healthy controls.
- Serum amyloid P-component (protein SAP) levels were measured using a quantitative assay.
Main Results:
- Patients with Waldenström's macroglobulinaemia exhibited markedly elevated protein SAP levels (83 +/- 34 micrograms/ml) compared to healthy controls (35 +/- 11 micrograms/ml) and multiple myeloma patients (39 +/- 17 micrograms/ml).
- Patients with seropositive rheumatoid arthritis and ankylosing spondylitis showed slightly elevated protein SAP levels compared to normals and systemic lupus erythematosus patients.
- These elevated levels in rheumatic disease patients were similar to those with amyloidosis associated with rheumatic disease.
Conclusions:
- Waldenström's macroglobulinaemia is associated with significantly increased serum amyloid P-component (protein SAP) levels.
- Protein SAP may serve as a potential biomarker in Waldenström's macroglobulinaemia.
- Further investigation is warranted to explore the role of protein SAP in rheumatic diseases and associated amyloidosis.